Robbie Majzner, MD
Physician, Cancer and Blood Disorders Center
Associate Professor of Pediatrics, Harvard Medical School
Image
Robbie Majzner, MD
Physician, Cancer and Blood Disorders Center
Associate Professor of Pediatrics, Harvard Medical School
Medical Services
Languages
English
Education
Medical School
Harvard Medical School
Boston
MA
Residency
Columbia/Morgan Stanley Children’s Hospital
New York
NY
Fellowship
National Cancer Institute and Johns Hopkins University
Baltimore
Certifications
American Board of Pediatrics (General)
American Board of Pediatrics (Hematology-Oncology)
Professional History
Robbie Majzner is the Director of the Pediatric and Young Adult Cancer Cell Therapy Program at Dana Farber Cancer Institute/Boston Children’s Hospital. He is focused on the development and deployment of immunotherapies for pediatric cancer. His work in the laboratory centers on engineering platform technologies to improve the efficacy of CAR T cells in solid tumors and overcome therapeutic resistance. Concurrently, he is focused on translating laboratory advances in innovative clinical trials for children with incurable cancers.
Publications
Immunotherapy-related cognitive impairment after CAR T cell therapy in mice. View Abstract
IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies. View Abstract
New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis. View Abstract
Author Correction: Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas. View Abstract
Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas. View Abstract
Orientation-dependent CD45 inhibition with viral and engineered ligands. View Abstract
Sequential intravenous and intracerebroventricular GD2-CAR T-cell therapy for H3K27M-mutated diffuse midline gliomas. View Abstract
Engineered CD47 protects T cells for enhanced antitumour immunity. View Abstract
Immunotherapy-related cognitive impairment after CAR T cell therapy in mice. View Abstract
INSPIRED Symposium Part 5: Expanding the Use of CAR T Cells in Children and Young Adults. View Abstract
Content-aware frame interpolation (CAFI): deep learning-based temporal super-resolution for fast bioimaging. View Abstract
Latent human herpesvirus 6 is reactivated in CAR T cells. View Abstract
Detection of Aberrant CD58 Expression in a Wide Spectrum of Lymphoma Subtypes: Implications for Treatment Resistance. View Abstract
Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy. View Abstract
Tumor inflammation-associated neurotoxicity. View Abstract
Co-opting signalling molecules enables logic-gated control of CAR T cells. View Abstract
Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. View Abstract
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. View Abstract
Enhanced T cell effector activity by targeting the Mediator kinase module. View Abstract
Time to resolution of iodine-123 metaiodobenzylguanidine (123 I-MIBG) avidity and local control outcomes for high-risk neuroblastoma following radiation therapy. View Abstract
Immunotherapy of Neuroblastoma: Facts and Hopes. View Abstract
Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1. View Abstract
Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. View Abstract
In vivo imaging of nanoparticle-labeled CAR T cells. View Abstract
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. View Abstract
Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication. View Abstract
GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity. View Abstract
NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity. View Abstract
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. View Abstract
Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force. View Abstract
Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins. View Abstract
How to stop using gadolinium chelates for magnetic resonance imaging: clinical-translational experiences with ferumoxytol. View Abstract
Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. View Abstract
Immune receptor inhibition through enforced phosphatase recruitment. View Abstract
PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors. View Abstract
Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report. View Abstract
Novel NanoLuc substrates enable bright two-population bioluminescence imaging in animals. View Abstract
Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. View Abstract
Tuning the Antigen Density Requirement for CAR T-cell Activity. View Abstract
Immune-Based Approaches for the Treatment of Pediatric Malignancies. View Abstract
c-Jun overexpression in CAR T cells induces exhaustion resistance. View Abstract
Clinical lessons learned from the first leg of the CAR T cell journey. View Abstract
CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. View Abstract
CAR T Cell Therapy for Neuroblastoma. View Abstract
Tumor Antigen Escape from CAR T-cell Therapy. View Abstract
Programming CAR-T cells to kill cancer. View Abstract
Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells. View Abstract
Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas. View Abstract
Neurotoxicity Associated with a High-Affinity GD2 CAR-Letter. View Abstract
New developments in immunotherapy for pediatric solid tumors. View Abstract
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. View Abstract
Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase. View Abstract
Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues. View Abstract
Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers. View Abstract
Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy. View Abstract
Pulmonary function after hematopoietic stem cell transplantation is significantly better in pediatric recipients following reduced toxicity compared with myeloablative conditioning. View Abstract
T cell depletion utilizing CD34(+) stem cell selection and CD3(+) addback from unrelated adult donors in paediatric allogeneic stem cell transplantation recipients. View Abstract